menu
    • menu
    [{"orgOrder":0,"company":"Ixaka","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"Rexmyelocel-T","moa":"Angiogenesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Ixaka","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intra-arterial Catheter","sponsorNew":"Ixaka \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ixaka \/ Undisclosed"},{"orgOrder":0,"company":"Ixaka","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Celtic","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Ixaka","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ixaka \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ixaka \/ Inapplicable"},{"orgOrder":0,"company":"Ixaka","sponsor":"Alaya.bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Celtic","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Ixaka","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ixaka \/ Alaya.bio","highestDevelopmentStatusID":"4","companyTruncated":"Ixaka \/ Alaya.bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Ixaka

    Menu

    Ixaka

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ixaka

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ixaka

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celtic

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Alaya.bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Alaya.bio Acquires Key Assets from Ixaka France, Accelerating the Progress of its Novel In Vivo CAR-T Immunoth...

                            Details : Through the acquisition, Alaya.bio intends to leverage its combined assets to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered.

                            Product Name : Celtic

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 20, 2023

                            Lead Product(s) : Celtic

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Alaya.bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ixaka

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ixaka

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Celtic

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ixaka Expands IP Portfolio to Enable Use of Targeted Nanoparticle in vivo Gene Delivery Technology With Any Ca...

                            Details : TNP – composed of proprietary polymer capsule ‘OM-PBAE’ polymers (oligopeptide end-modified poly β-amino-ester polymers) directed to specific cells through targeting agents attached capsule (an aptamer-based targeting moiety) and celtic (Lentiviru...

                            Product Name : Celtic

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 21, 2022

                            Lead Product(s) : Celtic

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ixaka

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ixaka

                            United Kingdom arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rexmyelocel-T

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $55.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ixaka (Formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company

                            Details : The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies and targeted nanoparticle therapeutics. REX-001, Ixaka’s lead MCT product, is an autologous cell-based product in clinical development fo...

                            Product Name : REX-001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 18, 2021

                            Lead Product(s) : Rexmyelocel-T

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $55.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth